Cargando…

Schistosomiasis—from immunopathology to vaccines

Schistosomiasis (bilharzia) is a neglected tropical disease caused by trematode worms of the genus Schistosoma. The transmission cycle involves human (or other mammalian) water contact with surface water contaminated by faeces or urine, as well as specific freshwater snails acting as intermediate ho...

Descripción completa

Detalles Bibliográficos
Autores principales: McManus, Donald P., Bergquist, Robert, Cai, Pengfei, Ranasinghe, Shiwanthi, Tebeje, Biniam Mathewos, You, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223304/
https://www.ncbi.nlm.nih.gov/pubmed/32076812
http://dx.doi.org/10.1007/s00281-020-00789-x
_version_ 1783533731954294784
author McManus, Donald P.
Bergquist, Robert
Cai, Pengfei
Ranasinghe, Shiwanthi
Tebeje, Biniam Mathewos
You, Hong
author_facet McManus, Donald P.
Bergquist, Robert
Cai, Pengfei
Ranasinghe, Shiwanthi
Tebeje, Biniam Mathewos
You, Hong
author_sort McManus, Donald P.
collection PubMed
description Schistosomiasis (bilharzia) is a neglected tropical disease caused by trematode worms of the genus Schistosoma. The transmission cycle involves human (or other mammalian) water contact with surface water contaminated by faeces or urine, as well as specific freshwater snails acting as intermediate hosts. The main disease-causing species are S. haematobium, S. mansoni and S. japonicum. According to the World Health Organisation, over 250 million people are infected worldwide, leading to considerable morbidity and the estimated loss of 1.9 million disability-adjusted life years (DALYs), a likely underestimated figure. Schistosomiasis is characterised by focal epidemiology and an over-dispersed population distribution, with higher infection rates in children. Complex immune mechanisms lead to the slow acquisition of immune resistance, but innate factors also play a part. Acute schistosomiasis, a feverish syndrome, is most evident in travellers following a primary infection. Chronic schistosomiasis affects mainly individuals with long-standing infections residing in poor rural areas. Immunopathological reactions against schistosome eggs trapped in host tissues lead to inflammatory and obstructive disease in the urinary system (S. haematobium) or intestinal disease, hepatosplenic inflammation and liver fibrosis (S. mansoni and S. japonicum). An effective drug—praziquantel—is available for treatment but, despite intensive efforts, no schistosomiasis vaccines have yet been accepted for public use. In this review, we briefly introduce the schistosome parasites and the immunopathogenic manifestations resulting from schistosomiasis. We then explore aspects of the immunology and host-parasite interplay in schistosome infections paying special attention to the current status of schistosomiasis vaccine development highlighting the advancement of a new controlled human challenge infection model for testing schistosomiasis vaccines.
format Online
Article
Text
id pubmed-7223304
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-72233042020-05-15 Schistosomiasis—from immunopathology to vaccines McManus, Donald P. Bergquist, Robert Cai, Pengfei Ranasinghe, Shiwanthi Tebeje, Biniam Mathewos You, Hong Semin Immunopathol Review Schistosomiasis (bilharzia) is a neglected tropical disease caused by trematode worms of the genus Schistosoma. The transmission cycle involves human (or other mammalian) water contact with surface water contaminated by faeces or urine, as well as specific freshwater snails acting as intermediate hosts. The main disease-causing species are S. haematobium, S. mansoni and S. japonicum. According to the World Health Organisation, over 250 million people are infected worldwide, leading to considerable morbidity and the estimated loss of 1.9 million disability-adjusted life years (DALYs), a likely underestimated figure. Schistosomiasis is characterised by focal epidemiology and an over-dispersed population distribution, with higher infection rates in children. Complex immune mechanisms lead to the slow acquisition of immune resistance, but innate factors also play a part. Acute schistosomiasis, a feverish syndrome, is most evident in travellers following a primary infection. Chronic schistosomiasis affects mainly individuals with long-standing infections residing in poor rural areas. Immunopathological reactions against schistosome eggs trapped in host tissues lead to inflammatory and obstructive disease in the urinary system (S. haematobium) or intestinal disease, hepatosplenic inflammation and liver fibrosis (S. mansoni and S. japonicum). An effective drug—praziquantel—is available for treatment but, despite intensive efforts, no schistosomiasis vaccines have yet been accepted for public use. In this review, we briefly introduce the schistosome parasites and the immunopathogenic manifestations resulting from schistosomiasis. We then explore aspects of the immunology and host-parasite interplay in schistosome infections paying special attention to the current status of schistosomiasis vaccine development highlighting the advancement of a new controlled human challenge infection model for testing schistosomiasis vaccines. Springer Berlin Heidelberg 2020-02-19 2020 /pmc/articles/PMC7223304/ /pubmed/32076812 http://dx.doi.org/10.1007/s00281-020-00789-x Text en © Springer-Verlag GmbH Germany, part of Springer Nature 2020, corrected publication 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review
McManus, Donald P.
Bergquist, Robert
Cai, Pengfei
Ranasinghe, Shiwanthi
Tebeje, Biniam Mathewos
You, Hong
Schistosomiasis—from immunopathology to vaccines
title Schistosomiasis—from immunopathology to vaccines
title_full Schistosomiasis—from immunopathology to vaccines
title_fullStr Schistosomiasis—from immunopathology to vaccines
title_full_unstemmed Schistosomiasis—from immunopathology to vaccines
title_short Schistosomiasis—from immunopathology to vaccines
title_sort schistosomiasis—from immunopathology to vaccines
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223304/
https://www.ncbi.nlm.nih.gov/pubmed/32076812
http://dx.doi.org/10.1007/s00281-020-00789-x
work_keys_str_mv AT mcmanusdonaldp schistosomiasisfromimmunopathologytovaccines
AT bergquistrobert schistosomiasisfromimmunopathologytovaccines
AT caipengfei schistosomiasisfromimmunopathologytovaccines
AT ranasingheshiwanthi schistosomiasisfromimmunopathologytovaccines
AT tebejebiniammathewos schistosomiasisfromimmunopathologytovaccines
AT youhong schistosomiasisfromimmunopathologytovaccines